Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. (28th May 2021) - Quach, Hang; Nooka, Ajay; Samoylova, Olga; Venner, Christopher P.; Kim, Kihyun; Facon, Thierry; Spencer, Andrew; Usmani, Saad Z.; Grosicki, Sebastian; Suzuki, Kenshi; Delimpasi, Sosana; Weisel, Katja; et al.